The Collegium Pharmaceutical Inc (COLL) Downgraded to Sell at Zacks Investment Research

The Collegium Pharmaceutical Inc (COLL) Downgraded to Sell at Zacks Investment Research

According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “

Zacks Investment Research cut shares of Collegium Pharmaceutical Inc (NASDAQ:COLL) from a hold rating to a sell rating in a report published on Wednesday, May 10th.

Several other equities analysts also recently weighed in on the company. Needham & Company LLC restated a buy rating and set a $28.00 price target (down from $30.00) on shares of Collegium Pharmaceutical in a report on Wednesday, April 19th. Jefferies Group LLC set a $24.00 price target on Collegium Pharmaceutical and gave the company a buy rating in a report on Saturday, March 25th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company has an average rating of Buy and an average price target of $22.40. Collegium Pharmaceutical (COLL) traded up 3.93% on Wednesday, hitting $9.53. 311,041 shares of the stock traded hands. Collegium Pharmaceutical has a 1-year low of $7.37 and a 1-year high of $20.55. The stock has a 50-day moving average price of $9.19 and a 200 day moving average price of $13.48. The company’s market cap is $280.73 million.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.98) by $0.19. The company had revenue of $2.17 million for the quarter, compared to the consensus estimate of $3.55 million. On average, analysts anticipate that Collegium Pharmaceutical will post ($3.07) EPS for the current fiscal year. In other news, insider Paul Brannelly bought 10,000 shares of the company’s stock in a transaction on Friday, May 12th. The shares were acquired at an average cost of $9.18 per share, with a total value of $91,800.00. Following the completion of the transaction, the insider now owns 110,227 shares of the company’s stock, valued at approximately $1,011,883.86. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 37.93% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in COLL. NBW Capital LLC boosted its position in Collegium Pharmaceutical by 1.8% in the first quarter. NBW Capital LLC now owns 62,030 shares of the specialty pharmaceutical company’s stock worth $624,000 after buying an additional 1,114 shares during the last quarter. Credit Suisse AG boosted its position in Collegium Pharmaceutical by 9.4% in the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 1,173 shares during the last quarter. Nationwide Fund Advisors boosted its position in Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 1,422 shares during the last quarter. American International Group Inc. boosted its position in Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after buying an additional 2,163 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Collegium Pharmaceutical by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock worth $656,000 after buying an additional 3,775 shares during the last quarter. 56.60% of the stock is currently owned by institutional investors and hedge funds. About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:COLL”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”}); Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Collegium Pharmaceutical Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Collegium Pharmaceutical Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment